Abcam, ab271891, Anti-Androgen Receptor antibody [EPR1535(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Androgen Receptor antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF and reacts with Mouse, Rat, Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR1535(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab271891 is the carrier-free version of
ab133273
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The androgen receptor (AR) also known as NR3C4 functions mechanically as a type of nuclear receptor that is activated by binding androgens including testosterone and dihydrotestosterone. The AR has a molecular weight of approximately 110 kDa. It is expressed in various tissues notably in the prostate skeletal muscle and certain areas of the brain. Within cells AR is usually located in the cytoplasm when unbound and translocates to the nucleus upon activation by its ligands.
Biological function summary
AR interacts with androgen hormones to regulate gene expression. It forms a complex with coactivators and corepressors to modulate transcription of target genes involved in male sexual development and reproductive function. AR plays an important role in the development and maintenance of male characteristics and reproductive activity. Its expression impacts cellular processes such as proliferation differentiation and apoptosis.
Pathways
AR is intricately involved in the androgen signaling pathway which affects the regulation of genes related to male sexual characteristics. It also plays a part in the PI3K/Akt pathway influencing cell growth and survival. The AR pathway interacts with proteins such as estrogen receptors to mediate cross-talk between hormonal pathways highlighting its broad biological impacts.
AR has a significant connection to prostate cancer where it drives tumor growth and progression. Mutations and overexpression of the androgen receptor are often observed in prostate cancer cells. Another condition linked to AR is androgen insensitivity syndrome where mutations in the AR gene result in partial or complete inability of cells to respond to androgenic hormones. In these conditions AR antagonists like bicalutamide are often used as treatment inhibiting the receptor's activity to manage disease progression.